- Eisai buys MGI Pharma
- Pfizer to help develop and market Eisai's Alzheimer's drug
- Eisai licenses rights to Zonegran from Elan
- Ligand sells cancer line to Eisai for $205mm
- Eisai to acquire US biotech Morphotek for $325mm
- Celgene buys Pharmion for $2.6bn in cash and stock
- Astellas buys Agensys for $387mm plus earn-outs
- Astellas develops antibodies using Regeneron's VelocImmune
- Otsuka buys PDL's IV Busulfex for $200mm
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.